Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease

Sara Renna, Fabio Salvatore Macaluso, Lucia Adamoli, Ambrogio Orlando, Antonio Cascio, Ambrogio Orlando, Sara Renna, Fabio Salvatore Macaluso

Risultato della ricerca: Article

7 Citazioni (Scopus)

Abstract

Objectives The treatment of inflammatory bowel disease (IBD) has been revolutionized by the use of immunomodulatory agents. Although these potent drugs are effective in controlling disease activity, they also cause an increased risk of new infections or reactivation of latent infections. On these premises, we aimed to provide guidance on the definitions of immunocompromised patients, opportunistic infections and the risk factors associated with their occurrence in an IBD context, and to suggest the proper screening tests for infectious diseases and the vaccination schedules to perform before and/or during therapy with immunomodulators. Methods All the most recent evidences – filtered by the combined work of gastroenterologists and infectious disease experts – were summarized with the aim to provide a practical standpoint for the physician. Results A systematic screening of all infections which may arise during therapy with immunomodulator drugs is necessary in all patients with IBD. Conclusions The ideal timing to perform screening tests and vaccinations is at the diagnosis of the disease, regardless of its severity at onset, because the course of IBD and its treatment may vary over time, and an immunocompromised status may hamper efficacy and/or possibility to perform all necessary vaccines.
Lingua originaleEnglish
pagine (da-a)433-441
Numero di pagine9
RivistaJournal of Infection
Volume74
Stato di pubblicazionePublished - 2017

Fingerprint

Inflammatory Bowel Diseases
Vaccines
Immunologic Factors
Infection
Communicable Diseases
Vaccination
Opportunistic Infections
Immunocompromised Host
Therapeutics
Pharmaceutical Preparations
Appointments and Schedules
Physicians

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cita questo

@article{d4de5e69202e410b8d7fd927482a6862,
title = "Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease",
abstract = "Objectives The treatment of inflammatory bowel disease (IBD) has been revolutionized by the use of immunomodulatory agents. Although these potent drugs are effective in controlling disease activity, they also cause an increased risk of new infections or reactivation of latent infections. On these premises, we aimed to provide guidance on the definitions of immunocompromised patients, opportunistic infections and the risk factors associated with their occurrence in an IBD context, and to suggest the proper screening tests for infectious diseases and the vaccination schedules to perform before and/or during therapy with immunomodulators. Methods All the most recent evidences – filtered by the combined work of gastroenterologists and infectious disease experts – were summarized with the aim to provide a practical standpoint for the physician. Results A systematic screening of all infections which may arise during therapy with immunomodulator drugs is necessary in all patients with IBD. Conclusions The ideal timing to perform screening tests and vaccinations is at the diagnosis of the disease, regardless of its severity at onset, because the course of IBD and its treatment may vary over time, and an immunocompromised status may hamper efficacy and/or possibility to perform all necessary vaccines.",
author = "Sara Renna and Macaluso, {Fabio Salvatore} and Lucia Adamoli and Ambrogio Orlando and Antonio Cascio and Ambrogio Orlando and Sara Renna and Macaluso, {Fabio Salvatore}",
year = "2017",
language = "English",
volume = "74",
pages = "433--441",
journal = "Journal of Infection",
issn = "0163-4453",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease

AU - Renna, Sara

AU - Macaluso, Fabio Salvatore

AU - Adamoli, Lucia

AU - Orlando, Ambrogio

AU - Cascio, Antonio

AU - Orlando, Ambrogio

AU - Renna, Sara

AU - Macaluso, Fabio Salvatore

PY - 2017

Y1 - 2017

N2 - Objectives The treatment of inflammatory bowel disease (IBD) has been revolutionized by the use of immunomodulatory agents. Although these potent drugs are effective in controlling disease activity, they also cause an increased risk of new infections or reactivation of latent infections. On these premises, we aimed to provide guidance on the definitions of immunocompromised patients, opportunistic infections and the risk factors associated with their occurrence in an IBD context, and to suggest the proper screening tests for infectious diseases and the vaccination schedules to perform before and/or during therapy with immunomodulators. Methods All the most recent evidences – filtered by the combined work of gastroenterologists and infectious disease experts – were summarized with the aim to provide a practical standpoint for the physician. Results A systematic screening of all infections which may arise during therapy with immunomodulator drugs is necessary in all patients with IBD. Conclusions The ideal timing to perform screening tests and vaccinations is at the diagnosis of the disease, regardless of its severity at onset, because the course of IBD and its treatment may vary over time, and an immunocompromised status may hamper efficacy and/or possibility to perform all necessary vaccines.

AB - Objectives The treatment of inflammatory bowel disease (IBD) has been revolutionized by the use of immunomodulatory agents. Although these potent drugs are effective in controlling disease activity, they also cause an increased risk of new infections or reactivation of latent infections. On these premises, we aimed to provide guidance on the definitions of immunocompromised patients, opportunistic infections and the risk factors associated with their occurrence in an IBD context, and to suggest the proper screening tests for infectious diseases and the vaccination schedules to perform before and/or during therapy with immunomodulators. Methods All the most recent evidences – filtered by the combined work of gastroenterologists and infectious disease experts – were summarized with the aim to provide a practical standpoint for the physician. Results A systematic screening of all infections which may arise during therapy with immunomodulator drugs is necessary in all patients with IBD. Conclusions The ideal timing to perform screening tests and vaccinations is at the diagnosis of the disease, regardless of its severity at onset, because the course of IBD and its treatment may vary over time, and an immunocompromised status may hamper efficacy and/or possibility to perform all necessary vaccines.

UR - http://hdl.handle.net/10447/290587

UR - http://www.elsevier.com/inca/publications/store/6/2/3/0/5/4/index.htt

M3 - Article

VL - 74

SP - 433

EP - 441

JO - Journal of Infection

JF - Journal of Infection

SN - 0163-4453

ER -